Braydon Meyer, Clare Stirzaker, Sonny Ramkomuth, Kate Harvey, Belinda Chan, Cheok Soon Lee, Rooshdiya Karim, Niantao Deng, Kelly A Avery-Kiejda, Rodney J Scott, Sunil Lakhani, Stephen Fox, Elizabeth Robbins, Joo-Shik Shin, Jane Beith, Anthony Gill, Loretta Sioson, Charles Chan, Mrudula Krishnaswamy, Caroline Cooper, Sanjay Warrier, Cindy Mak, John Ej Rasko, Charles G Bailey, Alexander Swarbrick, Susan J Clark, Sandra O'Toole, Ruth Pidsley
Phyllodes tumours (PTs) are rare fibroepithelial lesions of the breast that are classified as benign, borderline, or malignant. As little is known about the molecular underpinnings of PTs, current diagnosis relies on histological examination. However, accurate classification is often difficult, particularly for distinguishing borderline from malignant PTs. Furthermore, PTs can be misdiagnosed as other tumour types with shared histological features, such as fibroadenoma and metaplastic breast cancers. As DNA methylation is a recognised hallmark of many cancers, we hypothesised that DNA methylation could provide novel biomarkers for diagnosis and tumour stratification in PTs, whilst also allowing insight into the molecular aetiology of this otherwise understudied tumour...
February 1, 2024: Journal of Pathology